Patents by Inventor Paul Proost
Paul Proost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110028399Abstract: The present invention provides natural occurring, recombinant and synthetic chemokines, interleukins and cytokines in which at least one arginine residue is replaced by or modified into a cltrulline residue. The present Invention also relates to the use of said chemokines, interleukins or cytokines and pharmaceutical compositions comprising said chemokines, interleukins or cytokines as anti-inflammatory agents and as haematopoietic cell (including stem-cell, progenitor cell and leukocyte) or endothelial cell mobilizing agents. Furthermore, the present invention relates to the use of said chemokines, interleukins or cytokines to create antibodies and to use said chemokines, interleukins, cytokines and/or said antibodies as diagnostic tools and as a medicine. In addition, the present invention provides for the processes for the identification and production of the citrullinated chemokines, interleukins or cytokines of the invention.Type: ApplicationFiled: April 15, 2009Publication date: February 3, 2011Applicant: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Tamara Loos, Paul Proost, Jozef Van Damme
-
Publication number: 20090011981Abstract: The present invention provides novel inhibitors of angiogenesis. The invention relates to PF4var1 and fragments and modifications thereof with anti-angiogenic activity. Therefore, the present invention relates to the use of said proteins and peptides as a medicine, more in particular for the treatment or prevention of angiogenesis or for the manufacture of a medicament for the prevention or treatment of angiogenic diseases. The invention also provides pharmaceutical compositions comprising said proteins and peptides and method of preventing or treating angiogenic disorders.Type: ApplicationFiled: August 15, 2005Publication date: January 8, 2009Applicants: K.U. LEUVEN RESEARCH & DEVELOPMENT, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jozef Van Damme, Paul Proost, Sofie Struyf, Robert Strieter, Marie D. Burdick
-
Patent number: 7338653Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: GrantFiled: May 6, 2005Date of Patent: March 4, 2008Assignee: Laboratoires Serono SAInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Patent number: 7326411Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: GrantFiled: March 7, 2005Date of Patent: February 5, 2008Assignee: Laboratoires Serono SAInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Patent number: 6977071Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: GrantFiled: March 28, 2000Date of Patent: December 20, 2005Assignee: Applied Research Systems ARS Holding NVInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Publication number: 20050220790Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: ApplicationFiled: May 18, 2005Publication date: October 6, 2005Applicant: Applied Research Systems ARS Holding NVInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Publication number: 20050201977Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: ApplicationFiled: May 6, 2005Publication date: September 15, 2005Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.VInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Publication number: 20050164936Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: ApplicationFiled: March 7, 2005Publication date: July 28, 2005Applicant: Applied Research Systems ARS Holding NVInventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Patent number: 6905676Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: GrantFiled: March 28, 2000Date of Patent: June 14, 2005Assignee: Applied Research Systems ARS Holding N.V.Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Publication number: 20030124677Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: ApplicationFiled: March 28, 2000Publication date: July 3, 2003Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Publication number: 20030119148Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.Type: ApplicationFiled: March 28, 2000Publication date: June 26, 2003Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
-
Patent number: 5840524Abstract: This invention is directed to a new family of mammalian chemokine proteins, which have been designated granulocyte chemotactic protein-2 (GCP-2) proteins, and includes mammalian GCP-2, sequence-related variants of mammalian GCP-2, and distinct peptide fragments of GCP-2.Type: GrantFiled: May 24, 1995Date of Patent: November 24, 1998Assignee: Stichting Rega vzwInventors: Jo Van Damme, Paul Proost
-
Patent number: 5824551Abstract: The invention is based upon the newly recognized ability of .beta. chemokines to inhibit cell apoptosis. In particular, apoptosis of T cells is described. The known .beta. chemokines I-309 and TCA-3 are examples of the .beta. chemokines which inhibit apoptosis. One aspect of the invention is the use of these molecules to inhibit apoptosis. A second aspect of the invention is the use of .beta. chemokine inhibitors or antagonists to provoke apoptosis.Type: GrantFiled: October 10, 1995Date of Patent: October 20, 1998Assignee: Ludwig Institute For Cancer ResearchInventors: Jo Van Damme, Paul Proost, Frederic Houssiau, Jean-Christophe Renauld